Viking Therapeutics, Inc. (VKTX)
34.16
+0.92
(+2.78%)
USD |
NASDAQ |
Aug 25, 16:00
34.27
+0.12
(+0.34%)
After-Hours: 19:22
Viking Therapeutics Debt to Equity Ratio : 0.01 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.01 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.0002 |
| September 30, 2025 | 0.0011 |
| June 30, 2025 | 0.0011 |
| March 31, 2025 | 0.0012 |
| December 31, 2024 | 0.0013 |
| September 30, 2024 | 0.0014 |
| June 30, 2024 | 0.0012 |
| March 31, 2024 | 0.0013 |
| December 31, 2023 | 0.0036 |
| September 30, 2023 | 0.0036 |
| June 30, 2023 | 0.0037 |
| March 31, 2023 | 0.0111 |
| December 31, 2022 | 0.0108 |
| September 30, 2022 | 0.0108 |
| June 30, 2022 | 0.01 |
| March 31, 2022 | 0.009 |
| December 31, 2021 | 0.0001 |
| September 30, 2021 | 0.0005 |
| June 30, 2021 | 0.0009 |
| March 31, 2021 | 0.0012 |
| December 31, 2020 | 0.0015 |
| September 30, 2020 | 0.0017 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.002 |
| March 31, 2020 | 0.0022 |
| December 31, 2019 | 0.0024 |
| September 30, 2019 | 0.0026 |
| June 30, 2019 | 0.0028 |
| March 31, 2019 | 0.003 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.0512 |
| December 31, 2017 | 0.2563 |
| September 30, 2017 | 1.429 |
| June 30, 2017 | 0.463 |
| March 31, 2017 | 0.492 |
| December 31, 2016 | 0.4065 |
| September 30, 2016 | 0.2765 |
| June 30, 2016 | 0.1864 |
| March 31, 2016 | 0.5442 |
| December 31, 2015 | 0.2466 |
| September 30, 2015 | 0.3063 |
| June 30, 2015 | 0.2085 |
| March 31, 2015 | -0.1175 |
| June 30, 2014 | -0.072 |
| March 31, 2014 | -0.9223 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 0.0977 |
| Eli Lilly & Co. | 1.621 |
| Regeneron Pharmaceuticals, Inc. | 0.0854 |
| Skye Bioscience, Inc. | -0.3593 |
| Eledon Pharmaceuticals, Inc. | 0.0065 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 521.90M |
| Total Liabilities (Quarterly) | 113.58M |
| Shareholders Equity (Quarterly) | 408.32M |
| Current Ratio | 4.720 |
| Net Debt Paydown Yield | -0.01% |